Prior immunity protective against severe outcomes of COVID-19 infections in children
The evolution of SARS-CoV-2 variants and increasing immunity altered the impact of pediatric SARS-CoV-2 infection. Reliable and accurate clinical information reporting is critical for effective public health decision-making.
The data of a recent study has confirmed that prior immunity protects against severe outcomes of SARS-CoV-2 infections in children, similar to adults. This study is published in The Pediatric Infectious Disease Journal.
This study was an international hospital-based multicenter prospective cohort study. The real-time reporting was active from March 2020 to December 2022. In this study, researchers evaluated longitudinal incident rates and risk factors for disease severity.
Key results of this study are:
- Researchers included 564 hospitalized children with a history of acute COVID-19 in 375 children or multisystem inflammatory syndrome in children in 189 children from the Netherlands, Curaçao and Surinam.
- In COVID-19, 134 patients, constituting 36%, needed supplemental oxygen therapy, and 35 patients, including 9.3 %, required intensive care treatment.
- Predictors for severe COVID-19 included age above 12 years and preexisting pulmonary conditions.
- During omicron, Hospitalized children had milder disease.
- During population immunity, the incidence rate of pediatric COVID-19 infection declined for older children. It was stable for children below one year.
- The incidence rate of multisystem inflammatory syndrome in children was highest during the delta wave. It decreased rapidly since omicron emerged.
- Real-time reporting impacted national pediatric SARS-CoV-2 vaccination- and booster policies.
The COVID-19 pandemic has affected social and healthcare-related aspects worldwide. Healthcare decision-makers, medical staff, and hospital managers require reliable and updated information to make informed decisions.
The reporting framework of our consortium is readily accessible for future SARS-CoV-2 waves and other emerging infections, they said.
Study limitations include the observational nature of the study design, limited generalizability, reporting bias, etc.
Reference:
Tulling, Adam J. et al. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting. The Pediatric Infectious Disease Journal.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.